Vanda CEO Mihael Polymeropoulos called the drug a familiar therapeutic agent that offers flexible dosing with a well-known safety profile. April 1 Product: AstraZenecas Voydeya Indication: Paroxysmal nocturnal haemoglobinuria AstraZeneca kicked off April with a win for its rare disease portfolio as the FDA approved Voydeya, an oral, first-in-class factor D inhibitor to treat a subset of patients with paroxysmal nocturnal haemoglobinuria (PNH)
J., McGlone, F., & McGonigle, D
A.MurphyB.DanzerS
Additional examples of otoprotectants include, but are not limited to, Hes1/Hes5 SiRNA, Hes1 SiRNA, Hes5 SiRNA or other comparable modulators
In addition, Se supplementation improved hypothalamic-pituitary feedback to thyroid hormones, and thyroid stimulating hormone (TSH) returned to within the normal range, thereby reducing the stimulatory effect of TSH on thyroid tissue
Important: For external use only